$TNON
Tenon Medical, Inc.

2024 Q4 Form 10-Q Financial Statement

#000121390024098375 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $887.0K
YoY Change -6.04%
Cost Of Revenue $469.0K
YoY Change 14.67%
Gross Profit $418.0K
YoY Change -21.87%
Gross Profit Margin 47.13%
Selling, General & Admin $2.976M
YoY Change -6.3%
% of Gross Profit 711.96%
Research & Development $657.0K
YoY Change -10.85%
% of Gross Profit 157.18%
Depreciation & Amortization $105.0K
YoY Change 128.26%
% of Gross Profit 25.12%
Operating Expenses $3.633M
YoY Change -7.16%
Operating Profit -$3.215M
YoY Change -4.83%
Interest Expense $31.00K
YoY Change 675.0%
% of Operating Profit
Other Income/Expense, Net $31.00K
YoY Change -32.61%
Pretax Income -$3.184M
YoY Change -4.44%
Income Tax
% Of Pretax Income
Net Earnings -$3.184M
YoY Change -4.44%
Net Earnings / Revenue -358.96%
Basic Earnings Per Share -$3.63
Diluted Earnings Per Share -$3.63
COMMON SHARES
Basic Shares Outstanding 3.137M shares 3.952M shares
Diluted Shares Outstanding 877.0 shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.162M
YoY Change 171.79%
Cash & Equivalents $9.162M
Short-Term Investments
Other Short-Term Assets $543.0K
YoY Change 57.39%
Inventory $607.0K
Prepaid Expenses
Receivables $876.0K
Other Receivables $0.00
Total Short-Term Assets $11.19M
YoY Change 125.43%
LONG-TERM ASSETS
Property, Plant & Equipment $906.0K
YoY Change -5.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $482.0K
YoY Change -30.65%
Total Long-Term Assets $1.851M
YoY Change -21.4%
TOTAL ASSETS
Total Short-Term Assets $11.19M
Total Long-Term Assets $1.851M
Total Assets $13.04M
YoY Change 78.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.093M
YoY Change 43.25%
Accrued Expenses $908.0K
YoY Change 59.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.178M
YoY Change 3.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $1.670M
YoY Change -2.68%
Total Long-Term Liabilities $1.670M
YoY Change -2.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.178M
Total Long-Term Liabilities $1.670M
Total Liabilities $4.848M
YoY Change 0.98%
SHAREHOLDERS EQUITY
Retained Earnings -$65.66M
YoY Change 26.42%
Common Stock $3.000K
YoY Change 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.191M
YoY Change
Total Liabilities & Shareholders Equity $13.04M
YoY Change 78.18%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$3.184M
YoY Change -4.44%
Depreciation, Depletion And Amortization $105.0K
YoY Change 128.26%
Cash From Operating Activities -$2.343M
YoY Change -25.74%
INVESTING ACTIVITIES
Capital Expenditures $104.0K
YoY Change 76.27%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$104.0K
YoY Change -123.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.641M
YoY Change 3593.87%
NET CHANGE
Cash From Operating Activities -2.343M
Cash From Investing Activities -104.0K
Cash From Financing Activities 9.641M
Net Change In Cash 7.194M
YoY Change -392.44%
FREE CASH FLOW
Cash From Operating Activities -$2.343M
Capital Expenditures $104.0K
Free Cash Flow -$2.447M
YoY Change -23.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41364
dei Entity Registrant Name
EntityRegistrantName
TENON MEDICAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5574718
dei Entity Address Address Line1
EntityAddressAddressLine1
104 Cooper Court
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Gatos
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95032
dei City Area Code
CityAreaCode
(408)
dei Local Phone Number
LocalPhoneNumber
649-5760
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
TNON
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3136589 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9162000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2428000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
876000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
518000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
607000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
554000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
543000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
389000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
11188000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3889000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
906000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
961000 usd
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
51000 usd
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
51000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
463000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
646000 usd
CY2024Q3 us-gaap Deferred Costs
DeferredCosts
431000 usd
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
798000 usd
CY2024Q3 us-gaap Assets
Assets
13039000 usd
CY2023Q4 us-gaap Assets
Assets
6345000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1093000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
433000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
908000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
808000 usd
CY2024Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
898000 usd
CY2023Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
470000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
279000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
256000 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
0 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
77000 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1173000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3178000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3140000 usd
CY2024Q3 tnon Accrued Commissions Noncurrent
AccruedCommissionsNoncurrent
1454000 usd
CY2023Q4 tnon Accrued Commissions Noncurrent
AccruedCommissionsNoncurrent
1999000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
216000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
428000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
4848000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
5567000 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3136013 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3136013 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
325039 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
325039 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
70095000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
55897000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65659000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55073000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-46000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8191000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
778000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13039000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6345000 usd
CY2024Q3 us-gaap Revenues
Revenues
887000 usd
CY2023Q3 us-gaap Revenues
Revenues
944000 usd
us-gaap Revenues
Revenues
2507000 usd
us-gaap Revenues
Revenues
2120000 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
469000 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
409000 usd
us-gaap Cost Of Revenue
CostOfRevenue
1149000 usd
us-gaap Cost Of Revenue
CostOfRevenue
1438000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
418000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
535000 usd
us-gaap Gross Profit
GrossProfit
1358000 usd
us-gaap Gross Profit
GrossProfit
682000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
657000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
737000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2034000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2472000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1212000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1527000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4041000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5436000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1764000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1649000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5876000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5360000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
3633000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3913000 usd
us-gaap Operating Expenses
OperatingExpenses
11951000 usd
us-gaap Operating Expenses
OperatingExpenses
13268000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3215000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3378000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10593000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-12586000 usd
CY2024Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
31000 usd
CY2023Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
50000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
97000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
143000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
34000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-56000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
31000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
46000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
139000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3184000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3332000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10586000 usd
us-gaap Net Income Loss
NetIncomeLoss
-12447000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.63
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.63
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.69
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-18.6
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-18.6
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-63.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-63.18
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
877 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
877 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
285 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
285 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
569 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
569 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
197 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
197 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3184000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3332000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10586000 usd
us-gaap Net Income Loss
NetIncomeLoss
-12447000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
16000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-30000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
46000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-18000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3184000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3362000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10540000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12449000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
832000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
910000 usd
tnon Stock And Warrants Issued During Period Value Series B Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValueSeriesBPreferredStockAndWarrants
489000 usd
us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
3862000 usd
tnon Stock Issued During Period Value Issuance Of Common Stock And Warrants Under Inducement Agreement
StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsUnderInducementAgreement
4306000 usd
tnon Stock Issued During Period Value Issuance Of Common Stock Upon Exercise Of Warrants
StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants
812000 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
164000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3184000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8191000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
903000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1070000 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
453000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
289000 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3164000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-30000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3332000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2517000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
778000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2962000 usd
tnon Stock And Warrants Issued During Period Value Series A Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValueSeriesAPreferredStockAndWarrants
3554000 usd
tnon Stock And Warrants Issued During Period Value Series B Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValueSeriesBPreferredStockAndWarrants
489000 usd
us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
3862000 usd
tnon Stock Issued During Period Value Issuance Of Common Stock And Warrants Under Inducement Agreement
StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsUnderInducementAgreement
4306000 usd
tnon Stock Issued During Period Value Issuance Of Common Stock Upon Exercise Of Warrants
StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfWarrants
812000 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1968000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
46000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10586000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8191000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6252000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3164000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1644000 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
453000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
289000 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3164000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2000 usd
us-gaap Net Income Loss
NetIncomeLoss
-12447000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2517000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10586000 usd
us-gaap Net Income Loss
NetIncomeLoss
-12447000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2962000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3164000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
291000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
106000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
46000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
183000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
169000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
404000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
545000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
53000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
59000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
154000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
257000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
660000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
213000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
143000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-81000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-189000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-168000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7101000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9905000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
6996000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
493000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
223000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
269000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-223000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6234000 usd
tnon Proceeds From Issuance Of Series A Convertible Preferred Stock Net
ProceedsFromIssuanceOfSeriesAConvertiblePreferredStockNet
2437000 usd
tnon Proceeds From Issuance Of Series B Convertible Preferred Stock Net
ProceedsFromIssuanceOfSeriesBConvertiblePreferredStockNet
489000 usd
tnon Proceeds From Issuance Of Common Stock Prefunded Warrants And Warrants Net
ProceedsFromIssuanceOfCommonStockPrefundedWarrantsAndWarrantsNet
3862000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4306000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2106000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
453000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
812000 usd
tnon Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
4808000 usd
tnon Payments For Deferred Offering Costs
PaymentsForDeferredOfferingCosts
330000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14012000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4931000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-18000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6734000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1242000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2428000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2129000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9162000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3371000 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
1186000 usd
tnon Reclassification Of Deferred Offering Costs To Additional Paidin Capital
ReclassificationOfDeferredOfferingCostsToAdditionalPaidinCapital
238000 usd
tnon Warrant Modification Costs
WarrantModificationCosts
992000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>1. Organization and Business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Nature of operations</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Tenon Medical, Inc. (the “Company”) was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company that has developed The Catamaran™ SI Joint Fusion System (“the Catamaran System”) that offers a novel, less invasive approach to the sacroiliac joint (the “SI Joint”) using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. The Company received U.S. Food and Drug Administration (“FDA”) clearance in 2018 for The Catamaran System and is currently focused on the U.S. market. Since the national launch of the Catamaran System in October 2022, the Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) SI Joint fusion adjunct to a spine fusion construct.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Principles of consolidation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The condensed consolidated financial statements of the Company for the three and six months ended June 30, 2023 and as of December 31, 2023 include the accounts of its wholly-owned subsidiary, Tenon Technology AG (“TTAG”), a Swiss company. All intercompany balances and transactions have been eliminated in consolidation. The financial statements of TTAG are prepared for the same reporting period as the parent, using consistent accounting policies in all material respects. In 2024, TTAG was dissolved and, as such, the financial statements for the three and nine months ended September 30, 2024 and as of September 30, 2024 only include the accounts of the Company.</span></p>
CY2023Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10
CY2024Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-8
CY2024Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Use of estimates</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, accrued commissions, incremental borrowing rate, obsolescence of inventory, allowance for credit losses, and stock-based compensation.</span></p>
tnon Percentage Of Valuation Allowance In Deferred Tax Assets
PercentageOfValuationAllowanceInDeferredTaxAssets
1 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3650982 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
275605 shares
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1457000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1234000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
551000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
273000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
906000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
961000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
105000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
46000 usd
us-gaap Depreciation
Depreciation
278000 usd
us-gaap Depreciation
Depreciation
106000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
482000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
334000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
426000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
474000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
908000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
808000 usd
CY2024Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P2026Y
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
73000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
73000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
219000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
219000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
463000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
646000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
279000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
256000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
216000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
428000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
495000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
684000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
77000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
310000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
144000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
531000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
36000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
495000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
225000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
218000 usd
CY2024Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P1Y9M
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08 pure
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
55000 shares
CY2024Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.001
CY2024Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.55
CY2024Q3 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.125
CY2024Q3 us-gaap Equity Fair Value Disclosure
EquityFairValueDisclosure
992 usd
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5500000 usd
CY2023Q2 tnon Percentage Of Gross Proceeds
PercentageOfGrossProceeds
0.03 pure
us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
(i) up to 12,500 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $15.00 per share and (ii) up to 15,000 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $25.00 per share
tnon Purchase Exceed Amount
PurchaseExceedAmount
500000000 usd
us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
100000 shares
tnon Percentage Of Outstanding Shares
PercentageOfOutstandingShares
0.0499 pure
CY2024Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
10436 shares
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
910 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1070 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2962 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3164 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
250000 shares
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P5Y
CY2023Q2 tnon Class Of Warrants Of Rights Grant Date Fair Value Of Warrants
ClassOfWarrantsOfRightsGrantDateFairValueOfWarrants
3164
CY2023Q2 tnon Fair Value Of Offering Warrant
FairValueOfOfferingWarrant
12.64
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
24
CY2023Q2 tnon Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Daily Return Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDailyReturnRate
0.0518 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1 pure
CY2023Q2 tnon Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Standarddeviation
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStandarddeviation
0.063 pure
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y
CY2023Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
2377 usd
us-gaap Loss Contingency Accrual Payments
LossContingencyAccrualPayments
246 usd
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
6 usd
CY2024Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
2137 usd
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
usd
tnon Proceeds From Issuance Of Series A Convertible Preferred Stock Net
ProceedsFromIssuanceOfSeriesAConvertiblePreferredStockNet
usd
tnon Proceeds From Issuance Of Series B Convertible Preferred Stock Net
ProceedsFromIssuanceOfSeriesBConvertiblePreferredStockNet
usd
tnon Proceeds From Issuance Of Common Stock Prefunded Warrants And Warrants Net
ProceedsFromIssuanceOfCommonStockPrefundedWarrantsAndWarrantsNet
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
tnon Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
usd
tnon Payments For Deferred Offering Costs
PaymentsForDeferredOfferingCosts
usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
usd
tnon Reclassification Of Deferred Offering Costs To Additional Paidin Capital
ReclassificationOfDeferredOfferingCostsToAdditionalPaidinCapital
usd
tnon Warrant Modification Costs
WarrantModificationCosts
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001560293

Files In Submission

Name View Source Status
0001213900-24-098375-index-headers.html Edgar Link pending
0001213900-24-098375-index.html Edgar Link pending
0001213900-24-098375.txt Edgar Link pending
0001213900-24-098375-xbrl.zip Edgar Link pending
ea0220623-10q_tenon.htm Edgar Link pending
ea022062301ex31-1_tenon.htm Edgar Link pending
ea022062301ex31-2_tenon.htm Edgar Link pending
ea022062301ex32-1_tenon.htm Edgar Link pending
ea022062301ex32-2_tenon.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ea0220623-10q_tenon_htm.xml Edgar Link completed
tnon-20240930.xsd Edgar Link pending
tnon-20240930_cal.xml Edgar Link unprocessable
tnon-20240930_def.xml Edgar Link unprocessable
tnon-20240930_lab.xml Edgar Link unprocessable
tnon-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable